Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary interventionHiroki Watanabe, Shigeru Ikeguchi, Kiyoshi Hibi et al.|PLoS ONE|2018Cited by 128
Prognostic implications of anemia with or without chronic kidney disease in patients undergoing elective percutaneous coronary interventionYuichiro Kitai, Takeshi Kimura, Neiko Ozasa et al.|International Journal of Cardiology|2013Cited by 38
β-Blocker therapy and cardiovascular outcomes in patients who have undergone percutaneous coronary intervention after ST-elevation myocardial infarctionBingyuan Bao, Takeshi Kimura, Neiko Ozasa et al.|Cardiovascular Intervention and Therapeutics|2012Cited by 34
β-blocker use in patients after percutaneous coronary interventions: One size fits all? Worse outcomes in patients without myocardial infarction or heart failureNeiko Ozasa, Takeshi Kimura, Takeshi Morimoto et al.|International Journal of Cardiology|2012Cited by 31
Effects of Long-Term Carvedilol Therapy in Patients With ST-Segment Elevation Myocardial Infarction and Mildly Reduced Left Ventricular Ejection FractionMasashi Amano, Takeshi Kimura, Chisato Izumi et al.|The American Journal of Cardiology|2023Cited by 24